Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Sep 2025 value amounting to $164.8 million.

  • Crinetics Pharmaceuticals' Cash from Investing Activities rose 699.93% to $164.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 254.30%. This contributed to the annual value of -$574.8 million for FY2024, which is 186.82% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Cash from Investing Activities is $164.8 million, which was up 334.24% from $38.0 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash from Investing Activities ranged from a high of $164.8 million in Q3 2025 and a low of -$542.1 million during Q4 2024.
  • For the 3-year period, Crinetics Pharmaceuticals' Cash from Investing Activities averaged around -$59.9 million, with its median value being $309,000 (2024).
  • Data for Crinetics Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 699.93% (in 2025) and a maximum YoY decrease of 27,919.09% (in 2025) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$101.8 million in 2021, then soared by 136.20% to $36.9 million in 2022, then slumped by 336.91% to -$87.3 million in 2023, then tumbled by 520.89% to -$542.1 million in 2024, then surged by 699.93% to $164.8 million in 2025.
  • Its Cash from Investing Activities stands at $164.8 million for Q3 2025, versus $38.0 million for Q2 2025 and -$86.0 million for Q1 2025.